九福来(08611)发布公告，董事会建议采纳股份（301122）计划，以符合于2023年1月1日生效之经修订 GEM上市规则第23章。股份计划须待股东于股东特别大会上批准后，方可作实。 ...

Core Viewpoint - The company Jiu Fu Lai (08611.HK) announced a proposal for a share scheme that aligns with the revised GEM Listing Rules effective from January 1, 2023, which requires shareholder approval at a special meeting for implementation [1]. Summary by Relevant Sections - **Share Scheme Proposal** - The board of directors has recommended adopting a share scheme [1]. - The share scheme is contingent upon approval by shareholders at a special general meeting [1]. - The scheme will take effect once shareholders approve the ordinary resolution for its adoption [1].

证券代码：301122 证券简称：采纳股份 公告编号：2025-093 采纳科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 ...

Core Viewpoint - The medical device sector is experiencing significant activity, driven by government initiatives to enhance consumer product supply and promote innovation in health products, particularly in high-end medical devices and wearable technology [1][2]. Group 1: Market Activity - As of November 28, the medical device ETF (562600) rose by 0.23%, reaching a record size of 333 million yuan [1]. - Key stocks in the sector, including Kangwei Century, Mindray Medical (300760), and Yingke Medical (300677), showed positive performance [1]. Group 2: Government Initiatives - Six departments issued a plan to enhance the adaptability of consumer goods supply and demand, focusing on the innovation and development of health products [1]. - The plan emphasizes expanding the supply of specialized and new products, particularly in high-end medical devices and home health management applications [1]. Group 3: Internationalization of Domestic Medical Devices - Huachuang Securities noted that the internationalization of domestic medical device companies is progressing rapidly, with a significant increase in overseas certifications [1]. - According to data from Sullivan, medical devices are expected to account for 43.6% of China's medical device export trade in 2024, indicating a promising outlook for overseas expansion [1]. Group 4: Investment Opportunities - The medical device ETF (562600) tracks the CSI All Index Medical Device Index, which includes 100 representative companies, capturing 89.3% of the medical device industry [2]. - Investors can also consider alternative options such as the Huaxia CSI All Index Medical Device ETF Initiated Link A (021250) and Link C (021251) for convenient investment [2].

Core Viewpoint - The company, Canan Technology Co., Ltd., is experiencing fluctuations in stock performance and is benefiting from the depreciation of the RMB, particularly in its overseas revenue streams. Group 1: Company Overview - Canan Technology was established on July 23, 2004, and went public on January 26, 2022. The company is located in Jiangyin, Jiangsu Province, and specializes in the R&D, production, and sales of medical and veterinary injection and puncture instruments, as well as laboratory consumables [7]. - The main revenue components of the company include syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of November 20, the number of shareholders increased by 14.36% to 8,985, while the average circulating shares per person decreased by 12.55% to 8,418 shares [7]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86%. The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On November 26, the stock price of Canan Technology increased by 0.04%, with a trading volume of 59.69 million yuan and a turnover rate of 3.00%. The total market capitalization stands at 3.181 billion yuan [1]. - The company has seen a net inflow of 3.75 million yuan from major investors today, ranking 19th out of 132 in its industry, with a continuous increase in major investor positions over the past three days [4][5]. Group 4: Technical Analysis - The average trading cost of the stock is 27.79 yuan, with recent rapid outflows of shares suggesting a recommendation for portfolio adjustment. The current stock price is fluctuating between a resistance level of 27.16 yuan and a support level of 24.61 yuan, indicating potential for range trading [6]. Group 5: Industry Context - The company operates within the medical device sector, specifically focusing on medical consumables, and is positioned to benefit from trends in assisted reproduction and medical device markets, particularly due to its supply relationship with Thermo Fisher since 2018 [2][3].

Core Viewpoint - The company has announced the adoption of a share incentive plan to reward and motivate individuals contributing to its growth and development, effective November 20, 2025 [1] Group 1 - The board of directors has approved the share incentive plan as part of the company's strategy to incentivize key personnel [1] - The chairman, Wang Shugang, has been authorized to manage the incentive plan and handle all related matters [1]

智通财经APP讯，小菜园(00999)发布公告，为使公司可授予股份激励，作为对参与集团成长及发展的人 士的激励及回报的一部份，于2025年11月20日，董事会已议决采纳股份激励计划。本计划的激励股份主 要采取期权和受限制股份单位的形式，计划管理人可以根据公司具体情况决定发放其他形式的激励股 份。 ...

为确保成功落实计划，董事会授权董事长汪书高(公司执行董事、董事长兼总经理，控股股东之一)为激 励计划管理人，并全权办理股份激励计划相关事宜。 格隆汇11月25日丨小菜园(00999.HK)公布，为使公司可授予股份激励，作为对参与集团成长及发展之人 士的激励及回报的一部份，董事会欣然宣布，于2025年11月20日，董事会已议决采纳股份激励计划。 ...

Core Viewpoint - The company has adopted a share incentive plan to reward and motivate individuals contributing to its growth and development, effective from November 20, 2025 [1] Group 1 - The board has resolved to implement a share incentive plan (301122) [1] - The incentive shares will primarily be in the form of options and restricted share units [1] - The plan manager has the discretion to issue other forms of incentive shares based on the company's specific circumstances [1]

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.92% on November 21, with a trading volume of 81.41 million yuan and a total market capitalization of 3.115 billion yuan [1] Group 1: Company Overview - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018 [2] - The company's main business involves the research, production, and sales of injection and puncture instruments as well as laboratory consumables, with key products including puncture needles, syringes, laboratory consumables, and masks [2] - As of November 20, the number of shareholders in Canar Medical was 8,985, an increase of 14.36% from the previous period, while the average circulating shares per person decreased by 12.55% [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Dynamics - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the yuan [3] - The average trading cost of the stock is 27.89 yuan, with recent rapid outflows of shares suggesting a recommendation for portfolio adjustment [6]